SOURCE: Aoxing Pharmaceutical Co., Inc.

April 20, 2010 08:30 ET

Aoxing Pharmaceutical Company to Present at Deutsche Bank Access Asia Conference 2010

NEW YORK, NY--(Marketwire - April 20, 2010) - Aoxing Pharmaceutical Company Inc. (NYSE Amex: AXN) ("Aoxing Pharma") today announced that Aoxing Pharma is invited to present at Deutsche Bank Access Asia Conference 2010 in Singapore from May 10 to May 13, 2010.

Management at Aoxing Pharma will provide a recent update in financial performance, international business development as well as pipeline development. For further details, please contact your institutional sales representative.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its main operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships with QRxPharma and American Oriental Bioengineering, Inc. For more information:

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

  • For more information please contact:

    Aoxing Pharma Pharmaceutical Company

    Investor Relations Contact:
    Brian Korb
    Vice President
    The Troup Group LLC
    Tel: +1 646 378 2923